Edwards Lifesciences Stock Jumps on Q2 Earnings Beat and Raised Forecast

Edwards Lifesciences (NYSE: EW) shares rose on Wednesday after the company reported stronger-than-expected second-quarter financial results and raised its full-year sales forecast, boosting investor confidence in its growth trajectory.

The medical technology company posted adjusted earnings per share of $0.78 for the second quarter, exceeding the analyst consensus of approximately $0.74. Total revenue grew 12.5% year-over-year to $1.74 billion, also topping the estimated $1.70 billion, according to a report from Investing.com.

Upgraded Outlook and Segment Strength

Citing sustained demand for its products, Edwards Lifesciences management lifted the low end of its full-year 2026 sales growth guidance to a range of 10% to 11%. The company now projects total annual sales between $6.6 billion and $6.9 billion.

CEO Bernard Zovighian attributed the strong performance to growth from "multiple therapies across TAVR, mitral, tricuspid, and surgical," as noted in the report. Key segment highlights that beat expectations include:

Ad

• Transcatheter Mitral and Tricuspid Therapies (TMTT): Sales surged 44.8% year-over-year to $195.9 million.
• Transcatheter Aortic Valve Replacement (TAVR): Sales climbed 10.5% to $1.3 billion.

Wall Street Reaction

The positive results prompted several Wall Street analysts to raise their price targets for the stock. Leerink Partners upgraded its rating on Edwards Lifesciences from Market Perform to Outperform and increased its price target to $101 from $87.

Piper Sandler reiterated its Overweight rating while lifting its target to $101 from $100, and Bernstein raised its target to $99 from $96. The stock's advance came amid a relatively flat broader market, indicating the move was driven by company-specific news.